An emerging answer to the downstream bottleneck

BioProcess International

Volumn 10, Issue SUPPL. 5, 2012, Pages 58-61

  McGlaughlin, Molly S ^a  

^a Natrix Separations   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VACCINE;

BIOPROCESS; BIOTECHNOLOGICAL PRODUCTION; CATION EXCHANGE; CHROMATOGRAPHY; COMMERCIAL PHENOMENA; DOWNSTREAM PROCESSING; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PURIFICATION; ECONOMIC ASPECT; HUMAN; MEDICAL RESEARCH; PIPELINE; PRODUCTIVITY; SHORT SURVEY;

EID: 84863550018     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Ransohoff TC. Can Continuous Purification of Biopharmaceuticals Become a Reality? IBC's 7th International BMD Summit: San Diego, CA, 13 September 2011; www.bptc.com/sites/default/files/presentations/ransohoff-t-can-continuous- purification-of-biopharmaceuticals-become-a-reality-final.pdf.
2. Ransohoff TC. Global Trends in Mammalian Cell Culture Capacity and Biomanufacturing. Swiss Biotech Program at BioPharm America: Boston, MA, 6 September 2011; www.bptc.com/sites/default/files/presentations/ransohoff-t- global-trends-in-mammalian-cell-culture-capacity-and-biomanufacturing-rprint. pdf.
3. Medicines in Development: Biotechnology. Pharmaceutical Research and Manufacturers of America: Washington, DC, 2011; www.phrma.org/sites/default/ files/1776/biotech2011.pdf.
4. Langer E. 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations. BioPlan Associates: Rockville, MD, April 2011.
5. Levine H. Challenges in the CGMP Manufacturing of hESCs: Lessons Learned from Monoclonal Antibodies. ISCT 2011 Annual Meeting 18-21 may 2011, Rotterdam, The Netherlands.